Johnson & Johnson will pay a woman $55 million after claims that its talcum powder caused her to develop ovarian cancer.
Fox News Senior Judicial Analyst Judge Andrew Napolitano on Johnson and Johnson paying a woman $55 million over talcum-powder causing ovarian cancer.
Former drug executive Martin Shkreli, who last year became a lightning rod for outrage over soaring prescription drug prices, may face additional U.S. charges of securities fraud, a federal prosecutor said on Tuesday.
CVS Health reported an adjusted 1Q profit of $1.18 per share, topping the estimate for $1.16. Revenue for the company came in at $43.22 billion, beating the estimate for $43 billion.
Pfizer reported first-quarter revenue that blew past analysts' average estimate, boosted by sales of its new treatments for cancer and its Hospira acquisition.
Johnson & Johnson was ordered by a U.S. jury on Monday to pay $55 million to a woman who said that using the company’s talc-powder products for feminine hygiene caused her to develop ovarian cancer.
Former Health & Human Services Deputy Secretary Tevi Troy discusses the possible healthcare price surge in November.
Puerto Rico has 683 confirmed cases of the Zika virus, including 65 pregnant women with symptoms of the virus and one death, U.S. health officials said on Friday.
Valeant Pharmaceuticals International filed its overdue annual report on Friday morning, likely resolving the looming danger of debt default for the Canadian company.
Quest Diagnostics said it has received emergency authorization from the U.S. Food and Drug Administration to sell the first commercially developed diagnostic test for Zika in the United States, a step that may help expand testing capacity and speed diagnosis of the virus.
U.S. House of Representatives Speaker Paul Ryan called on Wednesday for an end to ObamaCare's financial protections for people with serious medical conditions, saying these consumers should be placed in state high-risk pools.
Following is a list of three stocks that ultra-rich investors have taken a position in, and some thoughts on whether you might want to follow their move.
Drugmaker AbbVie said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion in cash and stock.
Abbott Laboratories said it agreed to buy medical device maker St. Jude Medical for $25 billion to add heft to its heart and neurological devices business.
Aetna, which is in the process of buying rival Humana, reported first-quarter operating earnings that topped analysts' estimates as the health insurer added more members to its government plans.
French drugmaker Sanofi went public with a $9.3 billion offer to buy Medivation on Thursday, setting up what could be a lengthy takeover fight after the U.S. cancer firm rebuffed its approaches.
Valeant Pharmaceuticals International named Joseph Papa as its chief executive officer on Monday, the day after he resigned from the top spot at drugmaker Perrigo.
Drugmaker Perrigo has decided to let Chief Executive Officer Joseph Papa join Valeant Pharmaceuticals International as CEO and replace him with President John Hendrickson, according to people familiar with the matter.
As a company, I’ve become more and more enamored with Facebook. But what about the stock?
Drugmaker Valeant Pharmaceuticals International is seeking to appoint Perrigo boss Joseph Papa as its new chief executive, a source familiar with the matter said.